Skip to main content
Equibles
CAPR logo

CAPR · Capricor Therapeutics, Inc.

Track CAPR — free

Use CAPR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CAPR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.36 +1.07 (+12.91%) At close · Aug 26
Market Cap
$481.97M
Shares
58.14M

Capricor Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Capricor Therapeutics, Inc. (CAPR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $1.59M −$6.37M '22 Q3 22-11-10 · $2.99M −$7.77M '23 Q1 23-05-11 · $3.92M −$7.37M '23 Q2 23-08-07 ▲288.7% $6.19M −$6.39M '23 Q3 23-11-14 · $12.09M −$762,089 '23 Q4 24-02-29 ▲64.3% $4.91M −$9.79M '24 Q1 24-05-13 ▲1.4% $3.97M −$11.00M '24 Q2 24-08-07 LATEST ▼7.9% $11.13M −$7.12M '24 Q4 25-03-19
Earnings call
FY26 · Q2
2026-08-13
Capricor Therapeutics, Inc. (CAPR) Q2 2026 Earnings Call Transcript
Balanced tone Regulatory pathway and BLA amendment FDA Advisory Committee outcome Commercial readiness and manufacturing
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
Capricor Therapeutics, Inc. (CAPR) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Confident tone Commercial readiness and launch planning BLA regulatory path and HOPE-3 data Litigation against NS Pharma / Nippon Shinyaku
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Confident tone Deramiocel for DMD cardiomyopathy HOPE-3 Phase 3 trial data DVA patient-reported outcome (EAT 10 BITE)
Results not yet reported
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-03-11
Capricor Therapeutics, Inc. (CAPR) March 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-10
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
Confident tone HOPE-3 Phase 3 readout Regulatory pathway and CRL response Manufacturing and CMC
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Call Transcript
Positive tone Deramiocel for DMD Cardiomyopathy FDA Complete Response Letter and Regulatory Path HOPE-3 Phase 3 Trial and Endpoint Change
Diluted EPS
$-0.57
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Call Transcript
Confident tone BLA Approval and FDA Process HOPE-2 and HOPE-3 Clinical Data Label and Patient Identification
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-19
Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
Confident tone BLA Submission and Regulatory Progress Safety and Efficacy Data Commercial Launch Readiness
Revenue
$11.13M*
▼ 7.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-07
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Confident tone Deramiocel BLA submission and FDA pathway StealthX exosome platform pipeline Nippon Shinyaku partnership and milestones
Revenue
$3.97M
▲ 1.4% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
Confident tone HOPE-3 Phase 3 Trial and CAP-1002 for DMD Manufacturing and CMC (San Diego facility, potency assays) Regulatory progress with FDA (BLA readiness)
Revenue
$4.91M
▲ 64.3% YoY
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript
Confident tone BLA readiness, regulatory pathway, and FDA interactions Phase III HOPE-3 pivotal trial progress and interim results Financial position, milestones, and runway
Revenue
$12.09M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
Revenue
$6.19M
▲ 288.7% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
Revenue
$3.92M
Diluted EPS
$-0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
Revenue
$2.99M
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript
Revenue
$1.59M
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Capricor Therapeutics, Inc. (CAPR) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Capricor Therapeutics, Inc. (CAPR) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Capricor Therapeutics, Inc. (CAPR) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Capricor Therapeutics, Inc. (CAPR) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Capricor Therapeutics, Inc. (CAPR) Q2 2021 Earnings Call Transcript
Revenue
$204,082
▲ 309.3% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Capricor Therapeutics, Inc. (CAPR) Q1 2021 Earnings Call Transcript
Revenue
$40,816
▼ 78% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Capricor Therapeutics, Inc. (CAPR) Q4 2020 Earnings Call Transcript
Revenue
$57,830*
▼ 74% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-06
Capricor Therapeutics, Inc. (CAPR) Q2 2020 Earnings Call Transcript
Revenue
$49,864
▼ 87.8% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Capricor Therapeutics, Inc. (CAPR) Q1 2020 Earnings Call Transcript
Revenue
$185,693
▼ 19.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-18
Capricor Therapeutics, Inc. (CAPR) Q4 2019 Earnings Call
Revenue
$222,100*
▼ 65.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1133869 CUSIP 14070B309 13F (30d) 167 filings 163 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)